When Cancer Drugs Run Short, Patients Feel the Gap
A Washington Post report describes how some U.S. cancer patients and clinicians are turning to overseas sources when key medicines run short. The broader pattern reflects a stubborn reality: shortages can delay treatment, force substitutions, and create new safety questions.
Updated Menopause Guidance Reassesses Hormone Therapy
New guidance is putting hormone therapy back at the center of menopause care for some people with hot flashes and night sweats, while keeping safety limits and individual risk factors in view.
What consumers should know about unregulated peptide products
A Washington Post report highlights people who say they felt worse after using experimental peptides, while FDA warnings underline that many of these products have not been proven safe or effective.
What to Know Before Choosing a Galleri Cancer Blood Test
A Washington Post health column explores the appeal of Galleri, a multi-cancer blood test. The evidence suggests promise, but major questions remain about benefits, harms, and who should consider it.
A Chat Interface for Medical Devices Raises New Possibilities — and New Safety Questions
Researchers are testing an AI-powered platform that could let people exchange real-time messages with certain medical devices. The promise is faster feedback, but the safety and oversight questions are substantial.
AI Is Reshaping Breast Cancer Screening, but the Evidence Is Still Evolving
New imaging software is helping radiologists spot breast cancer risk and suspicious findings, but researchers say the benefits, limits, and best uses of AI are still being studied.
A New Sunscreen Ingredient Reaches U.S. Shelves After a Long FDA Review
Bemotrizinol is the first new U.S. sunscreen active ingredient in more than two decades, arriving as skin-cancer prevention remains a public health priority.
U.S. health officials move toward wider access to controversial peptide injections
The Trump administration is advancing a policy that could make certain unapproved peptide injections easier to compound, even as FDA materials continue to flag safety and quality concerns.
FDA maps out next wave of AI oversight for medical devices
The FDA’s new fiscal 2027 guidance list shows that artificial intelligence will remain a major focus, with planned documents on AI-enabled device software, generative AI, and related evidence standards.
Americans Worry AI Is Moving Faster Than Safeguards in Health Care
A new AP-NORC poll finds broad concern that artificial intelligence is advancing too quickly, a worry that carries special weight as AI tools expand in medicine and public health.